Can Weight Loss Drugs Cause Sudden Vision Loss: What Is NAION, the Rare Eye Condition Linked to Ozempic?

Weight-loss medicines such as Ozempic and Wegovy have transformed the treatment of obesity and Type 2 diabetes. However, questions have emerged about a possible link between these drugs and a rare eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION).

NAION can cause sudden, painless vision loss, usually in one eye. Although it is uncommon, the potential seriousness of the condition has drawn attention to the need to understand its symptoms, risk factors and possible association with medicines containing GLP-1 RAs. Importantly, a reported association does not mean that these medicines directly cause NAION. The risk appears to be low, and research is still examining the relationship.

What Is NAION?

“NAION is a condition in which blood flow to the front part of the optic nerve is reduced. The optic nerve carries visual information from the eye to the brain. When it does not receive enough blood and oxygen, its nerve fibres can become damaged, leading to vision loss,” explains Dr Shibal Bhartiya, Clinical Director - Ophthalmology, Marengo Asia Hospitals, Gurugram.

The condition is called non-arteritic because it is not caused by inflammation of the arteries. It is one of the common causes of sudden optic nerve-related vision loss in adults over 50. Unlike some eye conditions that develop gradually, NAION usually occurs suddenly and without pain. Vision loss can be permanent, although some people experience partial improvement.

What Are the Warning Signs of NAION ?

NAION generally affects one eye at a time. Its symptoms may include:

• Sudden, painless blurring or loss of vision in one eye
• A dark or missing area in the field of vision
• Difficulty seeing clearly, particularly in the lower or upper part of the visual field
• Colours appearing less bright than usual
• Reduced sharpness or haziness in vision
• Some people notice the change when they wake up in the morning

NOTE: Sudden or rapidly worsening vision loss should always be treated as an emergency and assessed immediately by an ophthalmologist.

Also Read: What Causes Pain In Only One Eye? 5 Warning Signs of Unilateral Eye Pain

Why Are Ozempic and Other Weight-Loss Drugs Being Linked to NAION?

Ozempic contains semaglutide, a medicine belonging to a class called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These medicines mimic a natural gut hormone that helps regulate blood sugar, appetite and food intake. Semaglutide is also sold under the brand names Wegovy and Rybelsus.

Research published in JAMA Network raised concerns about a possible association between semaglutide use and NAION. Subsequent studies have reported mixed findings, with some suggesting a higher risk and others finding no significant association.

On November 9, 2026, the US Food and Drug Administration (FDA) announced that it would require safety information about the potential risk of NAION to be added to the prescribing information of GLP-1 medicines. Its analysis of clinical trial data found 6.4 cases per 100,000 person-years among people taking these medicines, compared with 3.8 cases among those receiving comparator treatments.

However, this does not establish that the medicines directly cause the condition. More research is needed to understand the relationship.

Who Is More at Risk?

NAION can occur in people with certain underlying health conditions. Risk factors include:

• Type 2 diabetes
• High blood pressure
• High cholesterol
• Smoking
• Obstructive sleep apnoea
• Kidney disease
• Anaemia
• A crowded optic disc (small cup-to-disc ratio, sometimes called a disc at risk) is an important anatomical predisposition
• A history of NAION in one eye increases the risk of involvement of the other eye

People with diabetes may already have a higher risk of optic nerve-related complications, making it important to consider their overall health when assessing medication risks.

Also Read: Ozempic FAQs: Everything You Need To Know About The Weight Loss Drug

Should You Stop Taking Ozempic?

“No, patients should never discontinue these medicines independently. However, if NAION is diagnosed, the treating ophthalmologist and prescribing physician should urgently review the patient's treatment,” suggests Dr Bhartiya.

The FDA recommends considering discontinuation of the GLP-1 receptor agonist unless the benefits of continuing treatment clearly outweigh the potential risks.

Final Word

NAION is rare but potentially serious. While research has raised concerns about a possible link with certain diabetes and weight-loss medicines, the absolute risk remains low. Knowing the warning signs and seeking prompt eye care are essential.